Circulation October 12, 1999

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

Elliott M. Antman, Carolyn H. McCabe, Enrique P. Gurfinkel, et al.

Bottom Line

In patients with unstable angina or non-Q-wave myocardial infarction, acute treatment with the low-molecular-weight heparin enoxaparin significantly reduced the risk of death, nonfatal MI, and urgent revascularization compared to unfractionated heparin, though extended outpatient therapy offered no additional benefit and increased bleeding.

Key Findings

1. At 14 days, the primary composite endpoint of death, MI, or urgent revascularization occurred in 14.2% of the enoxaparin group versus 16.7% of the unfractionated heparin (UFH) group (relative risk reduction 14.9%, p=0.029) [9.1.3].

2. Clinical benefits were observed as early as 48 hours, with a 24% relative risk reduction in the primary endpoint (5.5% in the enoxaparin group vs. 7.3% in the UFH group, p=0.026).

3. At 43 days, the incidence of the primary composite endpoint remained significantly lower with enoxaparin (17.3%) compared to UFH (19.7%) (OR 0.85, p=0.048).

4. During the outpatient chronic phase (days 8 to 43), the rate of the primary endpoint was identical (2.9%) in patients receiving continued subcutaneous enoxaparin versus those receiving placebo.

5. Major hemorrhage during the acute phase did not differ significantly between the enoxaparin and UFH groups, but extended outpatient use of enoxaparin was associated with an increased risk of major bleeding without providing further ischemic benefit.

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

3,910

Patients

Duration

43 days

Median

Setting

Multinational

Population Patients presenting within 24 hours of ischemic rest discomfort (≥5 minutes duration) with unstable angina or non-Q-wave myocardial infarction, accompanied by ST-segment changes, positive cardiac markers, or a history of coronary artery disease.

Intervention Enoxaparin (30 mg IV bolus followed by 1.0 mg/kg subcutaneous injections every 12 hours) during the acute in-hospital phase, followed by continued outpatient subcutaneous enoxaparin for up to 43 days.

Comparator Intravenous unfractionated heparin (UFH) given as a 70 U/kg bolus and 15 U/kg/hr infusion (titrated to an aPTT of 1.5-2.5 times control) for ≥3 days, followed by outpatient subcutaneous placebo injections.

Outcome A composite of all-cause mortality, nonfatal myocardial infarction, or severe recurrent ischemia requiring urgent revascularization at 14 days and 43 days.

Study Limitations

• The prolonged, chronic outpatient administration of enoxaparin increased bleeding risk without providing additional efficacy, indicating the benefit is isolated to the acute phase.

• The trial was conducted before the widespread adoption of early invasive strategies (routine catheterization/PCI) and dual antiplatelet therapy for NSTE-ACS, limiting direct applicability to modern contemporary practice.

• Risk stratification relied on older cardiac biomarkers (e.g., CK-MB, standard troponins) rather than modern high-sensitivity troponin assays.

Clinical Significance

TIMI 11B established that enoxaparin is superior to continuous unfractionated heparin for the acute medical management of non-ST-segment elevation acute coronary syndromes (NSTE-ACS). The trial demonstrated that enoxaparin could effectively reduce adverse ischemic events without the need for constant aPTT monitoring. However, it also clearly delineated that while acute-phase LMWH is highly beneficial, prolonged outpatient administration does not reduce late ischemic events and introduces an unacceptable bleeding risk.

Historical Context

Prior to the publication of TIMI 11B (and the concurrently important ESSENCE trial), the standard of care for unstable angina and NSTEMI was continuous intravenous unfractionated heparin, which required frequent blood draws to adjust dosing via aPTT. By demonstrating superior efficacy and equivalent acute safety with a simpler, weight-based subcutaneous injection protocol, TIMI 11B spurred a major paradigm shift in cardiology guidelines, making low-molecular-weight heparins the standard antithrombotic bridge in acute coronary care until the advent of more contemporary oral agents and routine early invasive PCI approaches.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the pharmacological differences between enoxaparin (a low-molecular-weight heparin) and unfractionated heparin (UFH) that might explain enoxaparin's superior efficacy and more predictable pharmacokinetics in the acute management of NSTEMI?

Key Response

UFH inhibits both factor Xa and thrombin (IIa) equally and binds extensively to plasma proteins and endothelial cells, causing unpredictable dosing that requires frequent aPTT monitoring. Enoxaparin has a higher ratio of anti-factor Xa to anti-factor IIa activity, does not bind as extensively to plasma proteins, and has a longer half-life, allowing for weight-based, unmonitored subcutaneous dosing and a more consistent anticoagulant effect.

Resident

Based on the findings of TIMI 11B, how does the duration of enoxaparin therapy impact the balance of efficacy and bleeding risk in patients with NSTEMI, and what does this mean for discharge planning?

Key Response

TIMI 11B demonstrated that while the acute in-hospital administration of enoxaparin significantly reduces ischemic events compared to UFH, extending therapy into the outpatient setting (chronic phase) provides no additional ischemic benefit but significantly increases the risk of major bleeding. For residents, this dictates that therapeutic anticoagulation for ACS should be discontinued upon hospital discharge or following PCI, unless another specific indication (like atrial fibrillation or VTE) exists.

Fellow

In the contemporary era of early invasive strategies for NSTE-ACS, how do you reconcile the superiority of enoxaparin seen in TIMI 11B (a trial from the conservative management era) with later data regarding the risks of crossing over between UFH and LMWH prior to PCI?

Key Response

TIMI 11B established enoxaparin's efficacy primarily in patients managed medically. However, fellows must integrate this with later trials like SYNERGY, which showed that switching between UFH and enoxaparin before PCI increases bleeding complications without adding ischemic benefit. Consequently, contemporary practice emphasizes avoiding crossover; the anticoagulant initiated in the emergency department should generally be the one maintained throughout the percutaneous coronary intervention.

Attending

TIMI 11B fundamentally shifted the standard of care away from continuous UFH infusions for NSTEMI. When teaching trainees about this paradigm shift, what are the primary systems-based and patient-centered advantages of enoxaparin over UFH beyond the modest reduction in ischemic events?

Key Response

Beyond its ischemic benefits, enoxaparin revolutionized ACS care pathways by eliminating the need for continuous intravenous access, frequent aPTT blood draws, and complex nomogram-driven dose adjustments. This dramatically reduced nursing workload, minimized dosing errors, and facilitated earlier mobility and shorter hospital lengths of stay, providing an excellent teaching point on how predictable pharmacokinetics can drive massive systems-based improvements in healthcare delivery.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

TIMI 11B utilized a continuous two-phase, double-blind, double-dummy study design to evaluate both short-term superiority against UFH and long-term efficacy against placebo. What are the methodological advantages and potential confounding risks of using this continuous design for a single cohort?

Key Response

This design efficiently answers two clinical questions within one trial. However, it introduces methodological complexities such as carry-over effects from the acute phase, informative censoring, and survivor bias. Patients who suffer an event in the acute phase are removed or altered in the chronic phase, potentially unbalancing the randomization of the outpatient cohort and complicating the intention-to-treat analysis for the long-term extended therapy endpoint.

Journal Editor

In evaluating the TIMI 11B composite primary endpoint, a critical reviewer might scrutinize the inclusion of 'urgent revascularization'. How could the subjective nature of this specific endpoint introduce bias in this double-blind, double-dummy trial if accidental unblinding occurred?

Key Response

Urgent revascularization is a 'soft', physician-driven endpoint compared to objective measures like death or MI. Enoxaparin is administered subcutaneously and causes more injection site bruising than intravenous UFH (despite the use of placebo subQ injections to maintain the blind). If the double-dummy blinding was compromised by obvious hematomas, treating physicians might subconsciously lower their threshold for ordering urgent revascularization, potentially skewing the composite primary endpoint in favor of the unblinded therapy.

Guideline Committee

How did the findings of TIMI 11B directly inform current ACC/AHA and ESC guidelines regarding the choice and specifically the duration of parenteral anticoagulation in patients presenting with NSTE-ACS?

Key Response

TIMI 11B, alongside the ESSENCE trial, provided the foundational evidence to elevate LMWH (enoxaparin) to a Class I recommendation for acute NSTE-ACS management. Crucially, TIMI 11B's finding of increased bleeding without ischemic benefit in the outpatient phase directly informed the Class III (Harm) recommendation against the routine extended use of LMWH after hospital discharge for ACS, cementing the guideline that anticoagulation should be limited to the acute phase or until revascularization is performed.

Clinical Landscape

Noteworthy Related Trials

1997

ESSENCE Trial

n = 3,171 · NEJM

Tested

Enoxaparin 1 mg/kg subcutaneously twice daily

Population

Patients with angina at rest or non-Q-wave myocardial infarction

Comparator

Intravenous unfractionated heparin

Endpoint

Composite of death, MI, or recurrent angina at 14 days

Key result: Enoxaparin significantly reduced the risk of the primary composite endpoint compared to unfractionated heparin at 14 days and 30 days without significantly increasing major bleeding.

2004

SYNERGY Trial

n = 9,978 · JAMA

Tested

Enoxaparin subcutaneously

Population

High-risk NSTE-ACS patients planned for an early invasive strategy

Comparator

Intravenous unfractionated heparin

Endpoint

Composite of all-cause death or nonfatal MI at 30 days

Key result: Enoxaparin was non-inferior to unfractionated heparin for ischemic outcomes but was associated with a statistically significant increase in major bleeding.

2006

OASIS-5 Trial

n = 20,078 · NEJM

Tested

Fondaparinux 2.5 mg daily

Population

Patients with non-ST-segment elevation acute coronary syndromes

Comparator

Enoxaparin 1 mg/kg twice daily

Endpoint

Composite of death, MI, or refractory ischemia at 9 days

Key result: Fondaparinux was non-inferior to enoxaparin for ischemic events but halved the rate of major bleeding, which translated into significantly reduced 30-day mortality.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis